Urology of Virginia Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2006
NCT00274417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Urology of Virginia | Urology of Virginia Research | Urology of Virginia Research, Devine-Tidewater Urology

Active Ingredients

Drugs in Phase 3 Trials (1)

bupivacaine (Exparel) (1 trial)

Drugs in Other Trials (3)

degarelix acetate (firmagon) (1 trial)

dutasteride (avodart) (1 trial)

leuprolide (lupron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pain, Postoperative (Phase 3)

Urethral Stricture (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4